Table 3.
Patient, donor, and transplant characteristics for deceased and living donor transplants
| Characteristics | Deceased donor (N = 3237) | Living donor (N = 1487) | P‐value | Total cohort (N = 4724) |
|---|---|---|---|---|
| Patient | ||||
| Age at transplant, y, mean ± SD | 46.9 ± 14.1 | 42.3 ± 14.5 | <.001a | 45.4 ± 14.4 |
| Female sex, n (%) | 1309 (40.4) | 585 (39.4) | .47b | 1894 (40.1) |
| PRA at time of transplant, %, mean ± SD | 7.0 ± 19.0 | 3.8 ± 13.4 | <.001a | 6.0 ±17.5 |
| Highest PRA, %, mean ± SD | 16.5 ± 28.3 | 8.0 ± 17.9 | <.001a | 13.8 ± 25.8 |
| Dialysis, n (%) | <.001b | |||
| No | 150 (4.6) | 365 (24.6) | 515 (10.9) | |
| Yes—hemodialysis | 1879 (58.1) | 593 (39.9) | 2472 (52.3) | |
| Yes—peritoneal dialysis | 1189 (36.7) | 526 (35.4) | 1715 (36.3) | |
| Unknown | 19 (0.6) | 3 (0.2) | 22 (0.5) | |
| Time on dialysis, y, mean ± SD | 3.4 ± 2.6 | 1.3 ± 1.5 | <.001a | 2.8 ± 2.5 |
| Donor | ||||
| Donor age, y, mean ± SD | 42.8 ± 16.0 | 47.9 ± 11.9 | <.001a | 44.4 ± 15.0 |
| Donor female sex, n (%) | 1517 (47.9) | 869 (58.4) | <.001b | 2386 (50.5) |
| Cold ischemia time, h, mean ± SD | 21.9 ± 7.2 | 2.5 ± 1.5 | <.001a | 15.8 ± 10.8 |
| Transplant | ||||
| Retransplant, n (%) | 562 (17.4) | 161 (10.8) | <.001b | 723 (15.3) |
| HLA‐A/B/DR broad mismatches, mean ± SD | 2.2 ± 1.4 | 2.7 ± 1.6 | <.001a | 2.4 ± 1.5 |
| Induction therapy, n (%) | ||||
| IL‐2 receptor blocker | 655 (20.2) | 367 (24.7) | <.001b | 1022 (21.6) |
| T cell–depleting antibodyc | 133 (4.1) | 51 (3.4) | .26b | 184 (3.9) |
| Initial immunosuppression | ||||
| Steroids, n (%) | 3172 (98.0) | 1444 (97.1) | .058b | 4616 (97.7) |
| MMF/azathioprine | 3163 (76.1) | 442 (78) | <.001b | 3605 (76.3) |
| Cyclosporine/tacrolimus | 3051 (94.3) | 1383 (93.0) | .097b | 4434 (93.9) |
| Sirolimus | 176 (5.4) | 110 (7.4) | <.001b | 286 (6.1) |
| Other | 436 (13.5) | 172 (11.6) | .070b | 608 (12.9) |
| Unknown | 11 (0.3) | 6 (0.4) | .73b | 17 (0.4) |
DBD, donation after brain death; DCD, donation after cardiac death; DSA, donor‐specific HLA antibodies; IL, interleukin; MMF, mycophenolate mofetil.
a
Mann–Whitney U test for continuous variables.
b
χ2 test for categorical variables.
c
T cell–depleting antibody therapy: ALG, ATG, OKT3 monoclonal antibodies.